NO983669L - Coralyne analoger som topoisomeraseinhibitorer - Google Patents

Coralyne analoger som topoisomeraseinhibitorer

Info

Publication number
NO983669L
NO983669L NO983669A NO983669A NO983669L NO 983669 L NO983669 L NO 983669L NO 983669 A NO983669 A NO 983669A NO 983669 A NO983669 A NO 983669A NO 983669 L NO983669 L NO 983669L
Authority
NO
Norway
Prior art keywords
topoisomerase inhibitors
derivatives
coralyne
analogues
useful
Prior art date
Application number
NO983669A
Other languages
English (en)
Other versions
NO983669D0 (no
Inventor
Edmond J Lavoie
Leroy Fong Liu
Darshan B Makhey
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of NO983669D0 publication Critical patent/NO983669D0/no
Publication of NO983669L publication Critical patent/NO983669L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det blir fremskaffet protoberbinalkaloidderivater som er nyttige som anticancermidler og fremgangsmåter for anvendelsen av dem. Det blir også fremskaffet protoberberinde- rivater som er nyttige som topoisomeraseinhibitorer. Det blir videre fremskaffet kora- lyn- og nitidinderivater som er topoisomerase I målsøkende terapeutika som er effektive mot kamptotekinresistente cancerceller og er spesielt effektive mot sentralnervesystem- tumorer.
NO983669A 1996-02-12 1998-08-11 Coralyne analoger som topoisomeraseinhibitorer NO983669L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1145296P 1996-02-12 1996-02-12
US3216196P 1996-10-01 1996-10-01
PCT/US1997/001676 WO1997029106A1 (en) 1996-02-12 1997-02-11 Coralyne analogs as topoisomerase inhibitors

Publications (2)

Publication Number Publication Date
NO983669D0 NO983669D0 (no) 1998-08-11
NO983669L true NO983669L (no) 1998-09-23

Family

ID=26682407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983669A NO983669L (no) 1996-02-12 1998-08-11 Coralyne analoger som topoisomeraseinhibitorer

Country Status (18)

Country Link
EP (1) EP0888346B1 (no)
JP (1) JP2000504687A (no)
KR (1) KR19990082488A (no)
CN (1) CN1067070C (no)
AU (1) AU710070C (no)
BR (1) BR9707425A (no)
CA (1) CA2241551A1 (no)
CZ (1) CZ254498A3 (no)
DE (1) DE69705112T2 (no)
ES (1) ES2161442T3 (no)
HU (1) HUP9900413A3 (no)
IL (1) IL124803A0 (no)
NO (1) NO983669L (no)
NZ (1) NZ330705A (no)
PL (1) PL328402A1 (no)
PT (1) PT888346E (no)
TR (1) TR199801555T2 (no)
WO (1) WO1997029106A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW460464B (en) * 1996-11-25 2001-10-21 Nippon Kayaku Kk Novel phenanthridinium derivative having an anti-tumor activity and pharmaceutical composition containing the same
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
IL137351A0 (en) 1998-02-12 2001-07-24 Univ Rutgers Heterocyclic topoisomerase poisons
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CN1093129C (zh) * 1999-08-19 2002-10-23 广州市海科生物技术有限公司 一种具有抗肿瘤生理活性的尖叶唐松草阿原碱及其提取方法
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
MXPA04004607A (es) 2001-11-14 2004-09-10 Univ Rutgers Agentes de venenos de topoisomerasa solubilizados.
EP1453506B1 (en) 2001-11-14 2008-04-02 Rutgers, The State University Topoisomerase poison agents
EP1465625B1 (en) 2001-11-14 2010-02-03 Rutgers, The State University Solubilized topoisomerase poisons
US6992089B2 (en) 2002-08-09 2006-01-31 Rutgers, The University Of New Jersey Nitro and amino substituted topoisomerase agents
WO2004014918A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
EP1562593B1 (en) 2002-11-12 2014-07-16 Rutgers, The State University of New Jersey Topoisomerase-targeting agents
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
PL2346837T3 (pl) 2008-06-26 2015-07-31 Resverlogix Corp Sposoby wytwarzania pochodnych chinazolinonu
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ［ｉ］フェナントリジン誘導体
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
EP3431086B1 (en) 2009-04-22 2020-06-17 Resverlogix Corp. Novel anti-inflammatory agents
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
US8188109B2 (en) * 2009-07-20 2012-05-29 Naxospharma S.R.L. Benzoquinolizinium salt derivatives as anticancer agents
CN102746292B (zh) * 2011-04-18 2015-03-18 中国医学科学院医药生物技术研究所 环化的小檗碱衍生物及其制备方法和用途
HUE044986T2 (hu) 2011-11-01 2019-11-28 Resverlogix Corp Orális, azonnali felszabadulású készítmények szubsztituált kinazolinonokhoz
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US9642846B2 (en) 2013-03-15 2017-05-09 Georgetown University Antifungal drugs
EP3508204A1 (en) 2013-08-23 2019-07-10 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN107613769A (zh) * 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
CN105541714A (zh) * 2015-12-16 2016-05-04 浙江普洛康裕制药有限公司 一种罂粟碱及盐酸罂粟碱的制备方法
US11091498B2 (en) 2016-04-04 2021-08-17 Rutgers, The State University Of New Jersey Topoisomerase poisons
CN109843858B (zh) 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
CN110759963A (zh) * 2018-07-25 2020-02-07 中山大学 一种稠环类化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126351A (en) * 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
US5223506A (en) * 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds

Also Published As

Publication number Publication date
NZ330705A (en) 2000-03-27
PL328402A1 (en) 1999-01-18
TR199801555T2 (xx) 1998-11-23
NO983669D0 (no) 1998-08-11
PT888346E (pt) 2001-10-31
JP2000504687A (ja) 2000-04-18
CA2241551A1 (en) 1997-08-14
DE69705112T2 (de) 2002-03-21
HUP9900413A2 (hu) 1999-05-28
WO1997029106A1 (en) 1997-08-14
AU2115597A (en) 1997-08-28
CN1067070C (zh) 2001-06-13
CZ254498A3 (cs) 1998-12-16
EP0888346B1 (en) 2001-06-06
AU710070C (en) 2001-08-30
DE69705112D1 (en) 2001-07-12
BR9707425A (pt) 1999-07-20
AU710070B2 (en) 1999-09-16
HUP9900413A3 (en) 2002-02-28
EP0888346A1 (en) 1999-01-07
KR19990082488A (ko) 1999-11-25
CN1211252A (zh) 1999-03-17
ES2161442T3 (es) 2001-12-01
IL124803A0 (en) 1999-01-26

Similar Documents

Publication Publication Date Title
NO983669L (no) Coralyne analoger som topoisomeraseinhibitorer
EP1017675A4 (en) HIGHLY LIPOPHILIC CAMPTOTHECIN DERIVATIVES
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MX9307011A (es) Derivados hidrosolubles de camptotecina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
DK1660095T3 (da) Tricykliske PARP-inhibitorer
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
BR9508245A (pt) Método para inhibir metástase de cáncer por administração oral de pectina citrica modificada solúvel
MY133016A (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
MY116474A (en) Potentiation of temozolomide in human tumour cells
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
AU6797298A (en) Halo-alkoxycarbonyl prodrugs
EP1007553A4 (en) ZONULA OCCLUDENS TOXIN RECEPTORS
WO2002072021A3 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
DE69321254D1 (de) Quinuclidin derivate als squalene synthase inhibitoren
MX9304355A (es) Compuestos heterociclicos.
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
DE69902748D1 (de) Propargylamin enthaltende zusammensetzung zur verbesserung der krebstherapie
AU2620100A (en) Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
WO2001070093A3 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
WO2002048166A8 (en) Indolocarbazole anticancer agents and methods of using them
DE60030754D1 (de) Potenzierung der wirksamkeit von sn-38-prodrogen
AU2619700A (en) Pyridine compounds, use and preparation thereof
UA36385A (uk) Спосіб лікування генералізованого пародонтиту

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application